RECOVERY: World’s Largest COVID-19 Clinical Trial In the UK, the world’s largest clinical trial of potential coronavirus treatments, the Randomised Evaluation of COVID-19 Therapy trial (RECOVERY), is underway. It is aimed at assessing the effects of different treatments, including repurposed and novel drugs, on major outcomes in COVID-19.  You may also like: COVID-19 Will Revolutionise Imaging Practices The trial began on 19 March, and has been progress...

北京协和医院王春耀 ICU Management & Practice, Volume 20 - Issue 1, 2020 Personal Experience With Severe COVID-19 After 66 days in Wuhan COVID-2019 has become a worldwide pandemic. After working in Wuhan as intensive care physicians for 2 months, we have gained significant experience and would like to share our experience about daily care and supportive therapies for severe COVID-19 patients with our colleagues all over the world. The goal is for all of us to ...

ARTICLES|ONLINE FIRST Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, et al. Lancet Respir Med Published:March 31, 2020 DOI:https://doi.org/10.1016/S2213-2600(20)30037-0 Summary Background Tachycardia and atrial fibrillation frequently occur in patients bei...

ICU Management & Practice, Volume 20 - Issue 1, 2020 Tracheal Intubation in the ICU Making tracheal intubation safe for both patients and their health care providers. Introduction COVID-19 is a newly recognised viral infection which first appeared in Wuhan, China in late 2019. It is caused by a novel Coronavirus, Severe Acute Respiratory Syndrome-CoronaVirus-2. For the most part it results in a mild, self-limiting flu-like illness but unfortunately, s...

Research Letter May 21, 2020 Postmortem Examination of Patients With COVID-19 Tina Schaller, Klaus Hirschbühl, Katrin Burkhardt, et al JAMA. 2020;323(24):2518-2520. doi:10.1001/jama.2020.8907 Approximately 15% of individuals affected by coronavirus disease 2019 (COVID-19) develop severe disease, and 5% to 6% are critically ill (respiratory failure and/or multiple organ dysfunction or failure).1,2 Severely ill and critically ill patients have a high mortal...

COVID-19: Universal Masking in Hospitals The SARS-Cov-2 pandemic has all healthcare institutions scrambling for protocols to prevent virus transmission. The name of the game is to protect both patients and healthcare providers from the virus. However, every hospital has its protocol with respect to precautionary measures that have been undertaken to prevent transmission. While some hospitals advocate universal masking, other institutions are more selective and only enc...

Mechanical Ventilation in COVID-19 There is no specific treatment for COVID-19 patients. For those who develop respiratory failure and are unable to oxygenate with non-invasive methods, critical care doctors are providing supportive therapy. Since the pandemic started, mechanical ventilation has routinely been employed to oxygenate seriously ill COVID-19 patients. Each hospital has developed its own criteria for identifying patients who require mechanical ven...

Original Investigation June 23/30, 2020 Effect of Intraoperative Dexamethasone on Major Complications and Mortality Among Infants Undergoing Cardiac Surgery: The DECISION Randomized Clinical Trial Vladimir Lomivorotov, Igor Kornilov, Vladimir Boboshko, et al JAMA. 2020;323(24):2485-2492. doi:10.1001/jama.2020.8133 Abstract Importance Corticosteroids are widely used in pediatric cardiac surgery to blunt systemic inflammatory response and to...

Research Letter June 15, 2020 Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium Deborah Steensels, Els Oris, Laura Coninx, et al JAMA. Published online June 15, 2020. doi:10.1001/jama.2020.11160 Belgium has a high burden of coronavirus disease 2019 (COVID-19), especially the region surrounding the Hospital East-Limburg, a tertiary care center.1 Infection prevention measures were instituted in the hospital ...

ARTICLES|ONLINE FIRST GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al Lancet Rheumatol Published:June 16, 2020 DOI:https://doi.org/10.1016/S2665-9913(20)30170-3 Summary Background Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, a...